Difference between revisions of "Part:BBa K1391100:Design"

(→‎Design Notes)
(→‎Design Notes)
Line 7: Line 7:
  
 
===Design Notes===
 
===Design Notes===
−
This is an IgM antibody with a variable region identical to the IgG antibody Gantenerumab which has shown therapeutic potential as an antibody against beta amyloid. This antibody is membrane bound and meant to be used in conjunction with the Gantenerumab Kappa Light Chain, CD79A, and CD79B to form a B-Cell Receptor Complex for extracellular sensing of beta amyloid.
+
This is an IgM antibody with a variable region identical to the IgG antibody Gantenerumab which has shown therapeutic potential as an antibody against beta amyloid. This antibody is membrane bound and meant to be used in conjunction with the Gantenerumab Kappa Light Chain, CD79A, and CD79B to form a B-Cell Receptor Complex for extracellular sensing of beta amyloid. This particular chain has an IgM constant region fused to the Gantenerumab variable region and a leader sequence fused to the end of that for membrane localization.
  
 
===Source===
 
===Source===

Revision as of 15:42, 20 October 2014


pEXPR_Gantenerumab Variable Human Ig-M Heavy Chain


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal EcoRI site found at 306
    Illegal EcoRI site found at 480
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal EcoRI site found at 306
    Illegal EcoRI site found at 480
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal EcoRI site found at 306
    Illegal EcoRI site found at 480
    Illegal BglII site found at 1176
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal EcoRI site found at 306
    Illegal EcoRI site found at 480
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal EcoRI site found at 306
    Illegal EcoRI site found at 480
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

This is an IgM antibody with a variable region identical to the IgG antibody Gantenerumab which has shown therapeutic potential as an antibody against beta amyloid. This antibody is membrane bound and meant to be used in conjunction with the Gantenerumab Kappa Light Chain, CD79A, and CD79B to form a B-Cell Receptor Complex for extracellular sensing of beta amyloid. This particular chain has an IgM constant region fused to the Gantenerumab variable region and a leader sequence fused to the end of that for membrane localization.

Source

Fusion protein of 3 human peptide sequences

References